OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees by Nilsson, C et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Oral presentation
OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte 
proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara 
(MVA) heterologous boost vaccinees
C Nilsson*1, S Aboud2, K Karlén1, M Marovich3, B Wahren1, E Sandström4, 
HG a i n e s 1, G Biberfeld1 and K Godoy-Ramirez1
Address: 1Immunology and Vaccinology, Swedish Institute for Infectious Disease Control, Karolinska Institute, Solna, Sweden, 2Muhimbili 
University of Health and Allied Sciences, Dar es Salaam, Tanzania, 3Walther Reed Army Institute for Research, Rockville, MD, USA and 4Venhälsan 
and Karolinska Institutet, Stockholm, Sweden
* Corresponding author    
Background
We determined HIV-1-vaccine-induced lymphoprolifera-
tive responses in vaccinees immunized with a multigene,
multiclade HIV-1 plasmid DNA vaccine boosted with het-
erologous HIV-1 recombinant MVA in a phase I HIV safety
and immunogenicity study (HIVIS01/02).
Methods
Healthy volunteers were immunized intradermally or
intramuscularly (with or without adjuvant GM-CSF pro-
tein) with DNA expressing HIV-1 gag, env, rev and rt at
months 0, 1 and 3 using a Biojector and were boosted at
nine months with an MVA expressing heterologous inserts
of HIV-1 gag,  env  and  pol  genes. Lymphoproliferative
responses to AT-2 inactivated HIV-1 antigen were tested
by a 3H-thymidine uptake assay and a flow-cytometric
assay of specific cell-mediated immune-response in acti-
vated whole blood (FASCIA-WB) two weeks after HIV-1
MVA boost (n = 38). A FASCIA using peripheral blood
mononuclear cells (FASCIA-PBMC) was also employed
during the later part of the study (n = 14).
Results
Thirty-five of 38 (92%) vaccinees were reactive by the 3H-
thymidine-uptake assay (SI > 8). Thirty-two of 38 (84%)
vaccinees were reactive by the CD3+CD4+ T-cell FASCIA-
WB (% stimulation > 1.2), seven (18%) also exhibited
CD8+ (CD3+ CD4-) T-cell responses. Of the 14 vaccinees
analyzed using all three assays, ten (71%) and eleven
(79%) demonstrated CD4+ T-cell responses in FASCIA-
WB and FASCIA-PBMC, respectively. CD8+ T-cell reactiv-
ity was observed in 3 of 14 (21%) and 7 of 14 (50%) using
the FASCIA-WB and FASCIA-PBMC, respectively. There
was strong correlation between the proliferative responses
measured by the 3H-thymidine uptake assay and the
CD4+ T-cell FASCIA-WB (r = 0.68; p < 0.01).
Conclusion
HIV-1 specific T-lymphocyte proliferative responses were
detected in a high proportion (37/38) of volunteers fol-
lowing HIV-1 DNA/MVA immunization. The FASCIA
revealed both CD4+ and CD8+ T-cell proliferation in
response to HIV-1 antigen stimulation. A standardized
FASCIA-PBMC, which allows simultaneous phenotyping
may be an option to the conventional 3H-thymidine
uptake assay for assessment of vaccine-induced T-cell pro-
liferation, especially in isotope-restricted settings.
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